Skip to content

Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition

Intermittent Parasite Clearance (IPC) in Schools: a Randomised Double-blind Placebo-controlled Trial of the Impact of IPC on Malaria, Anaemia and Cognition Amongst School Children in Kedougou, Senegal

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01454752
Enrollment
860
Registered
2011-10-19
Start date
2011-11-30
Completion date
2012-02-29
Last updated
2012-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaemia, Malaria

Keywords

malaria, anaemia, cognition, intermittent preventive treatment, children, schools, insecticide-treated nets

Brief summary

Although the risk of malaria is greatest in early childhood, significant numbers of schoolchildren remain at risk from malaria infection, clinical illness and death. By the time they reach school, many children have already acquired some clinical immunity and the ability to limit parasite growth, and thus most infections are asymptomatic and will go undetected and untreated. Asymptomatic parasitaemia contributes to anaemia, reducing concentration and learning in the classroom, and interventions aiming to reduce asymptomatic parasite carriage may bring education, as well as health, benefits. Intermittent parasite clearance (IPC) delivered through schools is a simple intervention, which can be readily integrated into broader school health programmes, and may usefully supplement the community-distribution of insecticide-treated nets (ITNs) in countries with a policy of universal coverage of nets. This study seeks to establish whether intermittent parasite clearance undertaken once a year at the end of the malaria transmission season can reduce malaria parasite carriage and anaemia amongst school-going children already using insecticide-treated nets, and its consequent impact on school attendance and performance, in order to assess its suitability for inclusion as a standard intervention in school health programmes in areas of seasonal malaria transmission.

Interventions

DRUGIntermittent parasite clearance

Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days

OTHERPlacebo

Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days

Sponsors

Division Controle Medicale Scolaire, Ministry of Education, Senegal
CollaboratorUNKNOWN
Ministry of Health, Senegal
CollaboratorOTHER_GOV
Institut National d'Etude et d'Action pour le Developpement de l'Education, Senegal
CollaboratorUNKNOWN
Cheikh Anta Diop University, Senegal
CollaboratorOTHER
Institut de Recherche pour le Developpement, Senegal
CollaboratorOTHER
Harvard University
CollaboratorOTHER
London School of Hygiene and Tropical Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
7 Years to 14 Years
Healthy volunteers
Yes

Inclusion criteria

* enrolled in participating elementary schooled * provision of parental consent

Exclusion criteria

* lack of consent * chronic conditions which limit regular school attendance * clinical malaria on the day of scheduled treatment (as defined as febrile, with a positive result in a rapid diagnostic test for malaria).

Design outcomes

Primary

MeasureTime frame
Prevalence of malaria parasitaemia8 weeks after treatment (February 2012)
Prevalence of anaemia (Haemoglobin<11 g/dL)8 weeks after treatment (February 2012)

Secondary

MeasureTime frame
Cognitive performance in tests of sustained attention8 weeks after treatment (February 2012)

Countries

Senegal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026